Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250020/S005

Belotero Volume (+) Lidocaine Dermal Filler

Merz North America, Inc. · Decision date Sep 10, 2026

MEDTECHLEDGER EXPLANATIONP250020/S005

What did the FDA decide?

The FDA record P250020/S005 shows an OK30 decision dated 2026-09-10 for a 30-Day Notice submitted by Merz North America, Inc. The stated purpose is approval for requalification of the cleanroom and controlled manufacturing areas at Merz Aesthetics GmbH (FEI 3036164410), with Belotero Volume (+) Lidocaine Dermal Filler listed as the affected device. The record categorizes the supplement reason as Process Change - Manufacturer/Sterilizer/Packager/Supplier.

The S005 identifier places this supplement under PMA P250020, but the source statement describes a facility-level requalification of cleanroom and controlled manufacturing areas, not an original PMA or a new approval of the whole system. The fields do not specify which cleanroom parameters were requalified, what testing supported the requalification, or any clinical data; that information is absent from the supplied text. The OK30 order reflects the reported regulatory purpose and does not itself establish safety or clinical effectiveness.

The device category is listed as implant, dermal, for aesthetic use, with product code LMH and specialties General and Plastic Surgery.

FDA approval order statement

Approval for requalification of the cleanroom and controlled manufacturing areas at Merz Aesthetics GmbH facility (FEI 3036164410) affecting Belotero Volume (+) Lidocaine Dermal Filler
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
Sep 10, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250020/S005
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
OK30
Decision date
Sep 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P250020. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250020 · Original PMA

    Belotero Volume (+) Lidocaine

  2. P250020/S005 received

    Application receipt date recorded by FDA.

  3. P250020/S005 · FDA decision

    30-Day Notice

  4. P250020/S004 · Related supplement

    Belotero Volume (+) Lidocaine

Timeline entries are records held by MedtechLedger for P250020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250020

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA approvalMay 19, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Merz North America, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6501 Six Forks Rd., Raleigh, NC, 27615

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records